You are here: Industry Insights > Roche

News List

European Commission approves Roche’s tocilizumab to treat giant cell arteritis pharmaceufical-technology
September 26, 2017
Roche’s Actemra / RoActemra (tocilizumab) has received approval from the European Commission (EC) to treat giant cell arteritis (GCA).
Recipharm and Roche sign agreement to manufacture solid dose products pharmaceufical-technology
September 22, 2017
Swedish pharmaceutical company Recipharm has signed a long-term manufacturing agreement with Roche to produce a wide range of solid dose products.
Roche added to the hold group by FDA for combo immunotherapy trials pharmafile
September 20, 2017
The FDA has been working to make sure certain immunotherapy trials being placed on full or partial hold.
Roche and AbbVie's leukaemia combo smashes Phase 3 endpoint pharmafile
September 20, 2017
Venclexta/Venclyxto (venetoclax), Roche and AbbVie’s oral B-cell lymphoma-2 (BCL-2) inhibitor, successfully met its primary endpoint in Phase 3 trials
NICE rejects first-line use of Roche’s Gazyvaro pharmatimes
September 19, 2017
The National Institute for Health and Care Excellence has turned down first-line use of Roche’s Gazyvaro in patients with untreated advanced follicular lymphoma on the NHS in England and Wales.
Melanoma treatment: Novartis posts success, Roche stumbles pharmafile
September 12, 2017
In a perfect example of the competitive nature of the pharmaceutical industry, just as one company posted success in one particular area, another company was forced to reveal its failure in the same patient group.
Roche blood test can accurately predict immunotherapy efficacy pharmatimes
September 11, 2017
Data presented at ESMO has demonstrated that a new blood test from Roche, co-developed with Foundation Medicine, can accurately measure the number of mutations within a tumour
Roche’s Alecensa gets green light for early access scheme pharmatimes
September 05, 2017
UK patients with a rare form of lung cancer will be able to access Roche’s Alecensa without the need for prior chemotherapy before official approval is obtained, following its inclusion in the country’s Early Access to Medicines Scheme (EAMS).
Roche gets priority review for hyped hemophilia A prospect fiercebiotech
August 25, 2017
The FDA has granted priority review status to Roche’s hemophilia A candidate emicizumab, setting up the Swiss drugmaker to learn its fate by Feb. 23. Roche enters the review process armed with impressive efficacy data that risks being undermined by safety
Roche receives FDA Priority Review for drug with potted history pharmafile
August 25, 2017
Roche, alongside its subsidiary, Genentech, announced that it has received Priority Review for its haemophilia A drug, emicizumab, and that the agency has accepted its BLA.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page